awmsg logo



pramipexole (Mirapexin®)


Reference No. 608

Publication date:
01/06/2010


Appraisal information

pramipexole (Mirapexin®) prolonged-release tablet


Company: Boehringer Ingelheim Ltd
BNF category: Central nervous system
NMG meeting date: 17/03/2010
AWMSG meeting date: 28/04/2010
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0810
Ministerial ratification: 28/05/2010

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Pramipexole prolonged release (Mirapexin prolonged release®) is recommended as an option for use within NHS Wales for the treatment of the signs and symptoms of idiopathic Parkinson's disease, alone or in combination with levodopa. Pramipexole prolonged release should be initiated by a specialist experienced in the treatment of Parkinson's disease. AWMSG is of the opinion that pramipexole prolonged release may be suitable for shared care in accordance with appropriate local guidance. In order to limit potential errors, pramipexole prolonged release should be prescribed by brand as Mirapexin prolonged release®.
Final Appraisal Recommendation (FAR)
Download